184 related articles for article (PubMed ID: 25117082)
1. Identification of cancer stem cells and a strategy for their elimination.
Dolgova EV; Alyamkina EA; Efremov YR; Nikolin VP; Popova NA; Tyrinova TV; Kozel AV; Minkevich AM; Andrushkevich OM; Zavyalov EL; Romaschenko AV; Bayborodin SI; Taranov OS; Omigov VV; Shevela EY; Stupak VV; Mishinov SV; Rogachev VA; Proskurina AS; Mayorov VI; Shurdov MA; Ostanin AA; Chernykh ER; Bogachev SS
Cancer Biol Ther; 2014 Oct; 15(10):1378-94. PubMed ID: 25117082
[TBL] [Abstract][Full Text] [Related]
2. A strategy to eradicate well-developed Krebs-2 ascites in mice.
Potter EA; Dolgova EV; Proskurina AS; Minkevich AM; Efremov YR; Taranov OS; Omigov VV; Nikolin VP; Popova NA; Bayborodin SI; Ostanin AA; Chernykh ER; Kolchanov NA; Shurdov MA; Bogachev SS
Oncotarget; 2016 Mar; 7(10):11580-94. PubMed ID: 26872383
[TBL] [Abstract][Full Text] [Related]
3. Properties of internalization factors contributing to the uptake of extracellular DNA into tumor-initiating stem cells of mouse Krebs-2 cell line.
Dolgova EV; Potter EA; Proskurina AS; Minkevich AM; Chernych ER; Ostanin AA; Efremov YR; Bayborodin SI; Nikolin VP; Popova NA; Kolchanov NA; Bogachev SS
Stem Cell Res Ther; 2016 May; 7(1):76. PubMed ID: 27225522
[TBL] [Abstract][Full Text] [Related]
4. Delivery and processing of exogenous double-stranded DNA in mouse CD34+ hematopoietic progenitor cells and their cell cycle changes upon combined treatment with cyclophosphamide and double-stranded DNA.
Dolgova EV; Efremov YR; Orishchenko KE; Andrushkevich OM; Alyamkina EA; Proskurina AS; Bayborodin SI; Nikolin VP; Popova NA; Chernykh ER; Ostanin AA; Taranov OS; Omigov VV; Minkevich AM; Rogachev VA; Bogachev SS; Shurdov MA
Gene; 2013 Oct; 528(2):74-83. PubMed ID: 23911305
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profiling of tumor-initiating stem cells from mouse Krebs-2 carcinoma using a novel marker of poorly differentiated cells.
Potter EA; Dolgova EV; Proskurina AS; Efremov YR; Minkevich AM; Rozanov AS; Peltek SE; Nikolin VP; Popova NA; Seledtsov IA; Molodtsov VV; Zavyalov EL; Taranov OS; Baiborodin SI; Ostanin AA; Chernykh ER; Kolchanov NA; Bogachev SS
Oncotarget; 2017 Feb; 8(6):9425-9441. PubMed ID: 28031533
[TBL] [Abstract][Full Text] [Related]
6. Synergistic inhibition of tumor growth by combination treatment with drugs against different subpopulations of glioblastoma cells.
Chang CH; Liu WT; Hung HC; Gean CY; Tsai HM; Su CL; Gean PW
BMC Cancer; 2017 Dec; 17(1):905. PubMed ID: 29284440
[TBL] [Abstract][Full Text] [Related]
7. Chronometric Administration of Cyclophosphamide and a Double-Stranded DNA-Mix at Interstrand Crosslinks Repair Timing, Called "Karanahan" Therapy, Is Highly Efficient in a Weakly Immunogenic Lewis Carcinoma Model.
Ruzanova V; Proskurina A; Efremov Y; Kirikovich S; Ritter G; Levites E; Dolgova E; Potter E; Babaeva O; Sidorov S; Taranov O; Ostanin A; Chernykh E; Bogachev S
Pathol Oncol Res; 2022; 28():1610180. PubMed ID: 35693632
[No Abstract] [Full Text] [Related]
8. Bmi1 regulates human glioblastoma stem cells through activation of differential gene networks in CD133+ brain tumor initiating cells.
Vora P; Seyfrid M; Venugopal C; Qazi MA; Salim S; Isserlin R; Subapanditha M; O'Farrell E; Mahendram S; Singh M; Bakhshinyan D; Chokshi C; McFarlane N; Dvorkin-Gheva A; Brown KR; Murty N; Moffat J; Bader GD; Singh SK
J Neurooncol; 2019 Jul; 143(3):417-428. PubMed ID: 31115870
[TBL] [Abstract][Full Text] [Related]
9. A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells.
Visnyei K; Onodera H; Damoiseaux R; Saigusa K; Petrosyan S; De Vries D; Ferrari D; Saxe J; Panosyan EH; Masterman-Smith M; Mottahedeh J; Bradley KA; Huang J; Sabatti C; Nakano I; Kornblum HI
Mol Cancer Ther; 2011 Oct; 10(10):1818-28. PubMed ID: 21859839
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Notch signaling alters the phenotype of orthotopic tumors formed from glioblastoma multiforme neurosphere cells but does not hamper intracranial tumor growth regardless of endogene Notch pathway signature.
Kristoffersen K; Nedergaard MK; Villingshøj M; Borup R; Broholm H; Kjær A; Poulsen HS; Stockhausen MT
Cancer Biol Ther; 2014 Jul; 15(7):862-77. PubMed ID: 24755988
[TBL] [Abstract][Full Text] [Related]
11. CDC20 maintains tumor initiating cells.
Xie Q; Wu Q; Mack SC; Yang K; Kim L; Hubert CG; Flavahan WA; Chu C; Bao S; Rich JN
Oncotarget; 2015 May; 6(15):13241-54. PubMed ID: 25938542
[TBL] [Abstract][Full Text] [Related]
12. Girdin maintains the stemness of glioblastoma stem cells.
Natsume A; Kato T; Kinjo S; Enomoto A; Toda H; Shimato S; Ohka F; Motomura K; Kondo Y; Miyata T; Takahashi M; Wakabayashi T
Oncogene; 2012 May; 31(22):2715-24. PubMed ID: 22020337
[TBL] [Abstract][Full Text] [Related]
13. Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma.
Kang MK; Kang SK
Stem Cells Dev; 2007 Oct; 16(5):837-47. PubMed ID: 17999604
[TBL] [Abstract][Full Text] [Related]
14. Adenosine A3 receptor elicits chemoresistance mediated by multiple resistance-associated protein-1 in human glioblastoma stem-like cells.
Torres A; Vargas Y; Uribe D; Jaramillo C; Gleisner A; Salazar-Onfray F; López MN; Melo R; Oyarzún C; San Martín R; Quezada C
Oncotarget; 2016 Oct; 7(41):67373-67386. PubMed ID: 27634913
[TBL] [Abstract][Full Text] [Related]
15. Novel Cancer Stem Marker and Its Applicability for Grading Primary Human Gliomas.
Dolgova EV; Mishinov SV; Proskurina AS; Potter EA; Efremov YR; Bayborodin SI; Tyrinova TV; Stupak VV; Ostatin AA; Chernykh ER; Bogachev SS
Technol Cancer Res Treat; 2018 Jan; 17():1533034617753812. PubMed ID: 29375020
[TBL] [Abstract][Full Text] [Related]
16. Identification of internalizing human single-chain antibodies targeting brain tumor sphere cells.
Zhu X; Bidlingmaier S; Hashizume R; James CD; Berger MS; Liu B
Mol Cancer Ther; 2010 Jul; 9(7):2131-41. PubMed ID: 20587664
[TBL] [Abstract][Full Text] [Related]
17. Blocking distinct interactions between Glioblastoma cells and their tissue microenvironment: A novel multi-targeted therapeutic approach.
Mettang M; Meyer-Pannwitt V; Karpel-Massler G; Zhou S; Carragher NO; Föhr KJ; Baumann B; Nonnenmacher L; Enzenmüller S; Dahlhaus M; Siegelin MD; Stroh S; Mertens D; Fischer-Posovszky P; Schneider EM; Halatsch ME; Debatin KM; Westhoff MA
Sci Rep; 2018 Apr; 8(1):5527. PubMed ID: 29615749
[TBL] [Abstract][Full Text] [Related]
18. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
[TBL] [Abstract][Full Text] [Related]
19. Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation.
Xia S; Lal B; Tung B; Wang S; Goodwin CR; Laterra J
Neuro Oncol; 2016 Apr; 18(4):507-17. PubMed ID: 26320116
[TBL] [Abstract][Full Text] [Related]
20. Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin.
Zemp FJ; Lun X; McKenzie BA; Zhou H; Maxwell L; Sun B; Kelly JJ; Stechishin O; Luchman A; Weiss S; Cairncross JG; Hamilton MG; Rabinovich BA; Rahman MM; Mohamed MR; Smallwood S; Senger DL; Bell J; McFadden G; Forsyth PA
Neuro Oncol; 2013 Jul; 15(7):904-20. PubMed ID: 23585629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
